Abliva AB (OSTO:ABLI) Debt-to-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Abliva AB Debt-to-Asset?

Abliva AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Abliva AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Abliva AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was kr63.17 Mil. Abliva AB's debt to asset for the quarter that ended in Mar. 2024 was 0.00.

Abliva AB Debt-to-Asset Historical Data

The historical data trend for Abliva AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abliva AB Debt-to-Asset Chart

Abliva AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

Abliva AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Abliva AB's Debt-to-Asset

For the Biotechnology subindustry, Abliva AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abliva AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abliva AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Abliva AB's Debt-to-Asset falls into.

Abliva AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Abliva AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	87.499
	=	0.00

Abliva AB's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	63.17
	=	0.00

Abliva AB (OSTO:ABLI) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Abliva AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Abliva AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Abliva AB (OSTO:ABLI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (OSTO:ABLI) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

NEVPF:USA NTP:Germany

Address

Scheeletorget 1, Medicon Village, Lund, SWE, 223 81

Website

https://www.abliva.com

Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase.

Abliva AB (OSTO:ABLI) Headlines

No Headlines